Tradjenta (TRAD-gen-ta), a new gliptin for type 2 diabetes
Reps are promoting Tradjenta (TRAD-gen-ta), a new gliptin for type 2 diabetes.
Tradjenta (linagliptin) is a "me too"...similar to Onglyza (saxagliptin) and Januvia (sitagliptin). These prolong incretin activity to stimulate insulin and reduce glucagon release.
Tradjenta's only real claim to fame is that it doesn't require a lower dose for patients with impaired renal function.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: MD includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote